{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:24:01Z","timestamp":1785381841620,"version":"3.55.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bispecific antibodies (BsAb) targeting CD20 and CD3 have shown efficacy for relapsed\/refractory (R\/R) B-cell non-Hodgkin lymphoma (B-NHL), but their impact on outcomes following allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. In this international, retrospective study, we compared outcomes of adult patients with R\/R B-NHL undergoing first alloHCT after BsAb exposure (n = 47) versus a historical BsAb-na\u00efve cohort (n = 101). Baseline imbalances were addressed using inverse probability of treatment weighting (IPTW) and propensity score matching (PSM). The primary end point was nonrelapse mortality (NRM); secondary end points included overall survival (OS), progression-free survival (PFS), cumulative incidence of relapse (CIR), graft-versus-host disease (GVHD), engraftment, and GVHD\/relapse-free survival (GRFS). In the overall cohort, 2-year NRM did not differ significantly between BsAb-exposed and BsAb-na\u00efve groups (IPTW: 29.1% vs 31.4%, P = 0.80; PSM: 35.8% vs. 27.9%, P = 0.43). CIR was significantly lower in BsAb-exposed patients after IPTW (7.4% vs 20.0%, P = 0.01), but not in PSM (9.5% vs 23.4%, P = 0.06). OS, GVHD, GRFS, and engraftment were comparable. In a prespecified subanalysis limited to large B-cell lymphomas, CIR differences were consistent across IPTW (6.1% vs 21.1%, P = 0.01) and PSM (9.2% vs 33.3%, P = 0.03), reinforcing a potential benefit of prior BsAb therapy. A significant improvement in PFS was observed in this subgroup with IPTW (55.5% vs 36.6%; P = 0.04), but not in PSM (P = 0.20). Prior BsAb exposure does not adversely impact alloHCT safety and may be associated with improved disease control. Prospective studies are warranted to define optimal sequencing in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018152","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:56:43Z","timestamp":1768337803000},"page":"1843-1853","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6601-7276","authenticated-orcid":false,"given":"Marta","family":"Pe\u00f1a","sequence":"first","affiliation":[{"name":"1Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Bellvitge Biomedical Research Institute, Barcelona, Spain"},{"name":"2Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2640-3155","authenticated-orcid":false,"given":"Giulia","family":"Losi","sequence":"additional","affiliation":[{"name":"1Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Bellvitge Biomedical Research Institute, Barcelona, Spain"},{"name":"3Department of Hematology, Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-4605","authenticated-orcid":false,"given":"V\u00edctor","family":"Navarro","sequence":"additional","affiliation":[{"name":"4Statistics Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5297-9685","authenticated-orcid":false,"given":"David A.","family":"Qualls","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Crombie","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacopo","family":"Mariotti","sequence":"additional","affiliation":[{"name":"6Department of Oncology\/Hematology, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-7991","authenticated-orcid":false,"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[{"name":"6Department of Oncology\/Hematology, Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fabbri","sequence":"additional","affiliation":[{"name":"1Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Bellvitge Biomedical Research Institute, Barcelona, Spain"},{"name":"7Department of Hematology, Instituto di Ematologia Ser\u00e0gnoli, Universit\u00e0 di Bologna, Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7532-9634","authenticated-orcid":false,"given":"\u00c1ngel","family":"Serna","sequence":"additional","affiliation":[{"name":"8Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8751-5725","authenticated-orcid":false,"given":"Yasmina I. M.","family":"Serroukh","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Erasmus Medical Center Cancer Institute, University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aitana","family":"Balaguer-Rossell\u00f3","sequence":"additional","affiliation":[{"name":"10Hematology Department, Hospital Universitario La Fe de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein W. M.","family":"Van Der Poel","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-2812","authenticated-orcid":false,"given":"Ya-Ting","family":"Hsu","sequence":"additional","affiliation":[{"name":"12Division of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[{"name":"13Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"McKinnely","sequence":"additional","affiliation":[{"name":"14Hematology Department, Fiona Stanley Hospital, Murdoch, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1908-5596","authenticated-orcid":false,"given":"Luc\u00eda","family":"L\u00f3pez-Corral","sequence":"additional","affiliation":[{"name":"15Hospital Universitario de Salamanca, Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Panizo","sequence":"additional","affiliation":[{"name":"16Hospital Universitario de Donostia, San Sebastian, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[{"name":"17Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla, Consejo Superior de Investigaciones Cient\u00edficas, Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[{"name":"18Hematopoietic Cell Transplantation Unit, Hospital Cl\u00ednic de Barcelona, Institut Cl\u00ednic d'Hematologia i Oncologia, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Salda\u00f1a","sequence":"additional","affiliation":[{"name":"19Hospital de Jerez, Jerez de la Frontera, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[{"name":"20Department of Hematology, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3702-0817","authenticated-orcid":false,"given":"Carlos","family":"Solano","sequence":"additional","affiliation":[{"name":"21Hematology Department, Hospital Cl\u00ednico Universitario de Valencia-Instituto de Investigaci\u00f3n sanitaria del Hospital Cl\u00ednico Universitario de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[{"name":"8Servei d\u2019Hematologia, Vall d\u2019Hebron Hospital Universitari, Experimental Hematology, Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron Barcelona Hospital Campus, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Pascual-Casc\u00f3n","sequence":"additional","affiliation":[{"name":"22Hematology Department, Hospital Regional Universitario de M\u00e1laga, M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8931-5567","authenticated-orcid":false,"given":"V\u00edctor","family":"Noriega","sequence":"additional","affiliation":[{"name":"23Department of Hematology, Hospital Universitario de A Coru\u00f1a, A Coru\u00f1a, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6934-4619","authenticated-orcid":false,"given":"Jaime","family":"Sanz","sequence":"additional","affiliation":[{"name":"10Hematology Department, Hospital Universitario La Fe de Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9495-3555","authenticated-orcid":false,"given":"Andr\u00e9s","family":"S\u00e1nchez-Salinas","sequence":"additional","affiliation":[{"name":"24Hematology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Jurado","sequence":"additional","affiliation":[{"name":"25Department of Hematology, Hospital Universitario Virgen de las Nieves, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calbacho","sequence":"additional","affiliation":[{"name":"13Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-8617","authenticated-orcid":false,"given":"Leyre","family":"Bento","sequence":"additional","affiliation":[{"name":"26Hematology Department, Hospital Universitario Son Espases, Institut d'Investigaci\u00f3 Sanit\u00e0ria de les Illes Balears, Palma De Mallorca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6266-9397","authenticated-orcid":false,"given":"Carmen","family":"Albo L\u00f3pez","sequence":"additional","affiliation":[{"name":"27Hematology Department, Complexo Hospitalario Universitario de Vigo, Instituto de Investigaci\u00f3n Biom\u00e9dica Galicia Sur, Vigo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9649-4050","authenticated-orcid":false,"given":"Maria","family":"Perera","sequence":"additional","affiliation":[{"name":"28Department of Hematology, Hospital Universitario de Gran Canaria Dr Negr\u00edn, Las Palmas de Gran Canaria, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-0915","authenticated-orcid":false,"given":"Inmaculada","family":"Heras","sequence":"additional","affiliation":[{"name":"29Hematology Division, Hospital Morales Meseguer, Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-2578","authenticated-orcid":false,"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[{"name":"30Instituto Portugu\u00eas de Oncologia do Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1944-5040","authenticated-orcid":false,"given":"Pascual","family":"Balsalobre","sequence":"additional","affiliation":[{"name":"31Grupo Espa\u00f1ol de Trasplante de Progenitores Hematopoy\u00e9ticos y Terapia Celular, data office, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1238-6970","authenticated-orcid":false,"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"1Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Bellvitge Biomedical Research Institute, Barcelona, Spain"},{"name":"2Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4088-036X","authenticated-orcid":false,"given":"Alberto","family":"Mussetti","sequence":"additional","affiliation":[{"name":"1Clinical Hematology Department, Institut Catal\u00e0 d\u2019Oncologia-Hospitalet, Bellvitge Biomedical Research Institute, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"issue":"24","key":"2026032014064282600_bib1","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"10306","key":"2026032014064282600_bib2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"8","key":"2026032014064282600_bib3","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"3","key":"2026032014064282600_bib4","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s43018-025-00921-6","article-title":"Odronextamab monotherapy in patients with relapsed\/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","volume":"6","author":"Kim","year":"2025","journal-title":"Nat Cancer"},{"issue":"17","key":"2026032014064282600_bib5","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026032014064282600_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-024-00989-w","article-title":"Bi- and tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives","volume":"14","author":"Abou Dalle","year":"2024","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026032014064282600_bib7","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/cancers16091724","article-title":"Taking a BiTE out of lymphoma: bispecific antibodies in B-Cell non-Hodgkin lymphoma","volume":"16","author":"Weiss","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"2026032014064282600_bib8","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026032014064282600_bib9","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41409-021-01264-3","article-title":"Allogeneic stem cell transplantation as a curative option in relapse\/refractory diffuse large B cell lymphoma: Spanish multicenter GETH\/GELTAMO study","volume":"56","author":"Bento","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2026032014064282600_bib10","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1038\/s41375-021-01193-6","article-title":"Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma","volume":"35","author":"Merryman","year":"2021","journal-title":"Leukemia"},{"issue":"4","key":"2026032014064282600_bib11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"issue":"3","key":"2026032014064282600_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2026032014064282600_bib13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2026032014064282600_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"issue":"28","key":"2026032014064282600_bib15","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"3","key":"2026032014064282600_bib16","first-page":"1","article-title":"mice: Multivariate Imputation by Chained Equations in R","volume":"45","author":"van Buuren","year":"2011","journal-title":"J Stat Softw"},{"issue":"11","key":"2026032014064282600_bib17","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41409-023-02069-2","article-title":"Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas","volume":"58","author":"Pe\u00f1a","year":"2023","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2026032014064282600_bib18","first-page":"184.e1","article-title":"Haploidentical versus matched unrelated donor transplants using post-transplantation cyclophosphamide for lymphomas","volume":"29","author":"Mussetti","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"25","key":"2026032014064282600_bib19","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"2026032014064282600_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-024-01085-9","article-title":"Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for blood and marrow transplantation on more than 40,000 patients over 32 years","volume":"14","author":"Berning","year":"2024","journal-title":"Blood Cancer J"},{"issue":"10","key":"2026032014064282600_bib21","doi-asserted-by":"crossref","first-page":"806.e1","DOI":"10.1016\/j.jtct.2025.06.004","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation in relapsed\/refractory B-cell non-Hodgkin lymphoma: an Italian multicenter collaborative study","volume":"31","author":"Tarella","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2026032014064282600_bib22","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"issue":"16","key":"2026032014064282600_bib23","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1182\/bloodadvances.2024015406","article-title":"Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders","volume":"9","author":"Serna","year":"2025","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1843\/2508082\/blooda_adv-2025-018152-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/6\/1843\/2508082\/blooda_adv-2025-018152-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:06:54Z","timestamp":1774030014000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/6\/1843\/565992\/Allogeneic-HCT-as-consolidation-in-B-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018152","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,24]]},"published":{"date-parts":[[2026,3,11]]}}}